Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Prolonged viral shedding.. 65% Improvement Relative Risk c19hcq.org Hong et al. HCQ for COVID-19 EARLY TREATMENT Is early treatment with HCQ beneficial for COVID-19? Retrospective 90 patients in South Korea Improved viral clearance with HCQ (p=0.001) Hong et al., Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43 Favors HCQ Favors control
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Hong et al., Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43
Hong et al., Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication, Infect. Chemother., 2020, doi:10.3947/ic.2020.52.e43
Jul 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
HCQ 1-4 days from diagnosis was the only protective factor against prolonged viral shedding found, OR 0.111, p=0.001. 57.1% viral clearance with 1-4 days delay vs. 22.9% for 5+ days delayed treatment. Authors report that early administration of HCQ significantly ameliorates inflammatory cytokine secretion and that COVID-19 patients should be administrated HCQ as soon as possible. 42 patients with HCQ 1-4 days from diagnosis, 48 with HCQ 5+ days from diagnosis.
risk of prolonged viral shedding, early vs. late HCQ, 64.9% lower, RR 0.35, p = 0.001, treatment 42, control 48, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Hong et al., 16 Jul 2020, retrospective, South Korea, peer-reviewed, 7 authors, dosage not specified.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Infect Chemother. 2020 Sep;52(3):396-402 https://doi.org/10.3947/ic.2020.52.3.396 pISSN 2093-2340·eISSN 2092-6448 Brief Communication Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication Kyung Soo Hong Hong Nam Kim , Jong Geol Jang 1, Jian Hur 2, Jong Ho Lee , Wonhwa Lee 5,*, and June Hong Ahn 1,* 1 , 3 4,* Division of Pulmonology and Allergy, Department of Internal Medicine, College of Medicine, Yeungnam University and Regional Center for Respiratory Diseases, Yeungnam University Medical Center, Daegu, Korea 2 Division of Infection, Department of Internal Medicine, College of Medicine, Yeungnam University, Yeungnam University Medical Center, Daegu, Korea 3 Department of Laboratory Medicine, College of Medicine, Yeungnam University, Yeungnam University Medical Center, Daegu, Korea 4 Center for BioMicrosystems, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, Korea 5 Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea 1 Received: May 23, 2020 Accepted: Jun 29, 2020 Corresponding Author: Hong Nam Kim, PhD Center for BioMicrosystems, Brain Science Institute Korea Institute of Science and Technology, 5, Hwarang-ro 14 gil, Seongbukgu, Seoul 02792, Korea. Tel: +82-2-958-5617 Fax:+82-2-958-6910 E-mail: hongnam.kim@kist.re.kr Wonhwa Lee, PhD Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, 125 Gwahak-ro, Yuseong-gu, Daejeon 34141, Korea. Tel: +82-42-879-8143 Fax: +82-42-879-8596 E-mail: bywonhwalee@gmail.com ABSTRACT There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible. Keywords: Early; Hydroxychloroquine; Coronavirus disease 2019; Eradication *Hong Nam Kim, Wonhwa Lee, and June Hong Ahn corresponded equally to the work. Coronavirus disease 2019 (COVID-19) pneumonia outbreak, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection emerged in Wuhan, China in December 2019, rapidly spread to produce a worldwide pandemic [1]. There are no proven therapeutics for COVID-19, and current toll estimate more than 2.7 million infected people and almost 200 thousand deaths worldwide as of April 24 2020, according to data compiled by Johns Hopkins University. Recent studies have reported factors in association with prolonged duration of viral RNA shedding [2, 3]. But so far, no study has demonstrated the effects of antiviral drug administration on the duration of viral shedding and clinical improvement in COVID-19 patients. We investigated the time of antiviral drug administration in COVID-19 patients with factors and inhibitors associated with prolonged viral shedding, clinical improvement and cytokine storm, respectively. Copyright © 2020 by The Korean Society of Infectious Diseases, Korean Society for Antimicrobial Therapy, and The Korean Society for AIDS We..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit